DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinibECCO’23 CopenhagenYear: 2023
Authors: Dubinsky, M.C.(1)*;D'Haens, G.(2);Dewit, O.(3);Juillerat, P.(4);Panaccione, R.(5);Fujii, T.(6);Lacerda, A.P.(7);Dubcenco, E.(7);Anyanwu, S.(7);Doshi, C.(7);Mallick, M.(7);Garrison, A.(7);Liu, J.(7);Loftus Jr, E.V.(8);
(1)Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology, New York, United States;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands Antilles;(3)UCLouvain, Cliniques universitaires Saint-Luc, Brussels, Belgium;(4)Bern University Hospital, Clinic for Visceral Surgery and Medicine, Bern, Switzerland;(5)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(6)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(7)AbbVie Inc., Research and Development, North Chicago, United States;(8)Mayo Clinic School of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trialECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1);Rubin, D.T.(2);Panés, J.(3);Gecse, K.B.(4);Leung, Y.(5);Goetsch, M.(6);Wang, W.(7);Shan, K.(8);Woolcott, J.(9);Smith, C.C.(9);Wosik, K.(10);Schreiber, S.W.(11)*;
(1)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(2)University of Chicago Medicine, Section of Gastroenterology- Hepatology and Nutrition, Chicago- Illinois, United States;(3)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(4)Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands;(5)University of British Columbia, Gastroenterology, Vancouver- British Columbia, Canada;(6)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(7)Pfizer Inc, Biostatistics, Collegeville- Pennsylvania, United States;(8)Pfizer Inc, Global Project Development- Inflammation & Immunology, New York- New York, United States;(9)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(10)Pfizer Inc, Global Medical Affairs- Gastroenterology, Kirkland, Canada;(11)University Hospital Schleswig-Holstein- Department Internal Medicine I- Kiel University, Internal Medicine, Kiel, Germany;
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Chaparro, M.(1)*;Armuzzi, A.(2);Irving, P.M.(3,4);Allez, M.(5);Dubinsky, M.C.(6);Sands, B.E.(7);Goetsch, M.(8);Wang, W.(9);Shan, K.(10);Woolcott, J.(11);Bartolome, L.(12);Wosik, K.(13);Panaccione, R.(14);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Madrid, Spain;(2)IRCCS Humanitas Research Hospital- Rozzano, IBD Center, Milan, Italy;(3)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(4)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(5)Hôpital Saint Louis- Université Paris, Gastroenterology, Diderot, France;(6)Icahn School of Medicine- Mount Sinai, Feinstein IBD Center, New York- New York, United States;(7)Icahn School of Medicine- Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- New York, United States;(8)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(9)Pfizer Inc, Biostatistics, Collegeville- Pennsylvania, United States;(10)Pfizer Inc, Biostatistics, New York- New York, United States;(11)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(12)Pfizer Inc, Global Health Economics & Outcomes Research- Inflammation & Immunology, New York- New York, United States;(13)Pfizer Inc, Global Medical Affairs- Gastroenterology, Kirkland- Quebec, Canada;(14)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary- Alberta, Canada;
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patientsECCO’23 CopenhagenYear: 2023
Authors: Dignass, A.(1)*;Regueiro, M.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Vermeire, S.(5);Rubin, D.T.(6);
(1)Agaplesion Markus Hospital- Goethe University, Medicine, Frankfurt, Germany;(2)Cleveland Clinic, Digestive Disease and Surgery Institute, Cleveland, United States;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University Hospitals Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(6)The University of Chicago Medicine Inflammatory Bowel Disease, Gastroenterology, Chicago, United States;
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot studyECCO’23 CopenhagenYear: 2023
Authors: SinghD.M., A.(1)*;Midha, V.(2);Mahajan, R.(1);Kaur, K.(3);Singh, D.(4);Sood, A.(1);
(1)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;(3)Dayanand Medical College and Hospital, Pharmacology, Ludhiana, India;(4)Dayanand Medical College and Hospital, Research and Development, Ludhiana, India;
DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTEECCO’23 CopenhagenYear: 2023
Authors: Matsuoka, K.(1)*;Löwenberg, M.(2);Fumery, M.(3);Takatori, Y.(4);Fujitani, Y.(4);Oortwijn, A.(5);Faes, M.(6);Jamoul, C.(6);Hibi, T.(7);
(1)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Chiba, Japan;(2)University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)Amiens University Hospital, Department of Gastroenterology, Amiens, France;(4)Gilead Sciences, K.k., Tokyo, Japan;(5)Galapagos, Nv, Leiden, The Netherlands;(6)Galapagos, Nv, Mechelen, Belgium;(7)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Bourgonje, A.(1)*;Hu, S.(1);Gacesa, R.(1);Jansen, B.H.(1);Björk, J.R.(1);Bangma, A.(1);Hidding, I.J.(1);van Dullemen, H.M.(1);Visschedijk, M.C.(1);Faber, K.N.(1);Dijkstra, G.(1);Harmsen, H.J.M.(2);Festen, E.A.M.(1);Vich Vila, A.(1);Spekhorst, L.M.(1);Weersma, R.K.(1);
(1)University of Groningen- University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University of Groningen- University Medical Center Groningen, Medical Microbiology, Groningen, The Netherlands;
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitisECCO’23 CopenhagenYear: 2023
Authors: Liu, X.(1,2)*;Tang, H.(3);Zhou, Q.(1);Zeng, Y.(1,4);Lu, B.(1);Chen, M.(5);Xu, Y.(5);Wang, M.(5);Li, Y.(1);Tan, B.(1);Qian, J.(1);
(1)Peking Union Medical College Hospital- Peking Union Medical College & Chinese Academy of Medical Science, Department of Gastroenterology, Beijing, China;(2)Peking Union Medical College & Chinese Academy of Medical Science, Eight-year Medical Doctor Program, Beijing, China;(3)Peking Union Medical College Hospital- Peking Union Medical College & Chinese Academy of Medical Science, Department of Internal Medicine, Beijing, China;(4)Tsinghua University, School of Medicine, Beijing, China;(5)Peking Union Medical College Hospital- Peking Union Medical College & Chinese Academy of Medical Science, Department of Respiratory and Critical Care Medicine, Beijing, China;
DOP48: Key Anti-Inflammatory Faecalibacterium prausnitzii is Heterogeneous and Diverse in the East and West and in Health and Crohn's disease. The ENIGMA study.ECCO’23 CopenhagenYear: 2023
Authors: Teh, J.J.(1);Kang, S.(1);Leonard, A.(1);Zhang, J.(2,3,4);Hu, J.(2,3,4);Hamilton, A.L.(5,6);Wilson-O'Brien, A.(5,6);Trakman, G.L.(5,6);Lin, W.(2,3,4);Ching , J.(2,4);Sung, J.J.Y.(7);Yu, J.(2,4);Ng, S.C.(2,3,8);Kamm, M.A.(5,6)*;Morrison, M.(1);
(1)University of Queensland, Frazer Institute, Woolloongabba, Australia;(2)The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China;(3)Microbiota I-Center, MagIC, Hong Kong, China;(4)Li Ka Shing Institute of Health Sciences, State Key Laboratory of Digestive Disease, Hong Kong, China;(5)Saint Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(6)University of Melbourne, Department of Medicine, Melbourne, Australia;(7)Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore;(8)The Chinese University of Hong Kong, Center for Gut Microbiota Research, Hong Kong, China;
DOP49: Metagenomic Characterisation of The Colonic Mucosa-Associated Microbiota Reveals Novel Microbes and Communities in Health and Crohn's disease. The ENIGMA study.ECCO’23 CopenhagenYear: 2023
Authors: Kang, S.(1);Teh, J.J.(1);Zhang, J.(2,3,4);Hu, J.(2,3,4);Hamilton, A.L.(5,6);Wilson-O'Brien, A.(5,6);Trakman, G.L.(5,6);Lin, W.(2,3,4);Ching, J.(2,4);Sung, J.J.Y.(7);Yu, J.(2,4);Ng, S.C.(2,3,8);Kamm, M.A.(5,6)*;Morrison, M.(1);
(1)University of Queensland, Frazer Institute, Woolloongabba, Australia;(2)The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China;(3)Microbiota I-Center, MagIC, Hong Kong, China;(4)Li Ka Shing Institute of Health Sciences, State Key Laboratory of Digestive Disease, Hong Kong, China;(5)Saint Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(6)University of Melbourne, Department of Medicine, Melbourne, Australia;(7)Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore;(8)The Chinese University of Hong Kong, Center for Gut Microbiota Research, Hong Kong, China;
DOP50: Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiotaECCO’23 CopenhagenYear: 2023
Authors: Grellier, N.(1,2,3)*;Suzuki, M.(4);Brot, L.(1);Rodrigues, A.(4);Humbert, L.(1);Escoubeyrou, K.(4);Rainteau, D.(1);Grill, J.P.(1);Lami, R.(4);Seksik, P.(1,3);
(1)Sorbonne Université, Saint-Antoine Research Center, Paris, France;(2)Centre Hospitalier Universitaire de Poitiers, Hepato-gastroenterology department, Poitiers, France;(3)Saint-Antoine hospital, Department of Gastroenterology, Paris, France;(4)Sorbonne Université, Laboratoire de Biodiversité et Biotechnologies Microbiennes, Banyuls-sur-mer, France;
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: HagemanMD, I.(1)*;Joustra, V.(2);Zafeiropoulou , K.(1);Davids, M.(3);Hakvoort, T.(1);Probert, F.(4);Satsangi, J.(5);D'Haens, G.(2);De Jonge, W.(1);
(1)Tytgat Institute for Liver and Intestinal Research, Department of Gastroenterology & Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)Amsterdam UMC, Laboratory of Experimental Vascular Medicine, Amsterdam, The Netherlands;(4)Chemistry Research Laboratory- Oxford University, Department of Chemistry, Oxford, United Kingdom;(5)Translational Gastroenterology Unit- NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust- John Radcliffe Hospital, Oxford, United Kingdom;On behalf of the EPIC-Pioneer consortium
DOP52: The faecal bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn's disease and the modifying effects of exclusive enteral nutrition and re-introduction of habitual dietECCO’23 CopenhagenYear: 2023
Authors: Gerasimidis, K.(1)*;Nichols, B.(1);Papadopoulou, R.(1);Ijaz, U.(2);Rajendran, R.(3);Quince, C.(4);Russell, R.K.(5);Hansen, R.(6);Ramage, G.(3);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)University of Glasgow, School of Engineering, Glasgow, United Kingdom;(3)University of Glasgow, Dental School, Glasgow, United Kingdom;(4)Earlham Institute, Organisms and Ecosystems, Norwich, United Kingdom;(5)Royal Hospital for Sick Children and Young People, Paediatric Gastroenterology- Hepatology and Nutrition, Edinburgh, United Kingdom;(6)Royal Hospital for Children, Paediatric Gastroenterology- Hepatology and Nutrition, Glasgow, United Kingdom;
DOP53: Community types of the human gut virome are associated with endoscopic outcome in UC patientsECCO’23 CopenhagenYear: 2023
Authors: Jansen, D.(1)*;Falony, G.(2);Vieira-Silva, S.(3);Simsek, C.(1);Marcelis, T.(1);Machiels, K.(4);Caenepeel, C.(4);Raes, J.(2);Severine, V.(4);Matthijnssens, J.(1);
(1)Lab of Viral Metagenomics, Department of Microbiology- Immunology and Transplantation, Leuven, Belgium;(2)Laboratory of Molecular Bacteriology, Department of Microbiology- Immunology and Transplantation, Leuven, Belgium;(3)Institute of Medical Microbiology and Hygiene, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany;(4)Translational Research Center for Gastrointestinal Disorders TARGID, University Hospitals Leuven, Leuven, Belgium;
DOP54: Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn's disease – a systematic review and network meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Attauabi, M.(1,2)*;Steenholdt, C.(1);Burisch, J.(2,3);Gubatan, J.(4);Nielsen, O.H.(1);Seidelin, J.B.(1);
(1)Copenhagen University Hospital - Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(2)Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents- and Adults, Hvidovre, Denmark;(3)Copenhagen University Hospital - Amager and Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(4)Stanford University School of Medicine, Division of Gastroenterology and Hepatology, Stanford, Denmark;
DOP56: Long-term disease progression and resective surgery rates in Crohn's disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohortECCO’23 CopenhagenYear: 2023
Authors: Gonczi, L.(1);Lakatos, L.(2)*;Golovics, P.A.(3);Pandur, T.(4);David, G.(2);Erdélyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(5);
(1)Semmelweis University, Department of Medicine and Oncology, Budapest, Hungary;(2)Ferenc Csolnoky Hospital, Department of Gastroenterology, Veszprem, Hungary;(3)Hungarian Defence Forces Medical Centre, Department of Gastroenterology, Budapest, Hungary;(4)Grof Esterhazy Hospital, Department of Gastroenterology, Papa, Hungary;(5)Mcgill University Health Center, IBD Centre, Montréal, Canada;
DOP57: GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort studyECCO’23 CopenhagenYear: 2023
Authors: Christensen, H.S.(1)*;Andersen, D.(2);Jess, T.(2);Allin, K.H.(2);
(1)Aalborg University, PREDICT- Department of Clinical Medicine, Aalborg, Denmark;(2)Aalborg University, PREDICT- Department of Clinical Medicine, Copenhagen, Denmark;
DOP58: predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRNECCO’23 CopenhagenYear: 2023
Authors: Lujan, R.(1);Atia, O.(1);Gili, F.(1)*;Greenfeld, S.(2);Kariv, R.(2);Loewenberg Weisband, Y.(3);Lederman, N.(4);Matz, E.(5);Dotan, I.(6);Turner, D.(1);
(1)Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Israel and the Sackler Faculty of Medicine, Maccabi Health Services, Tel Aviv, Israel;(3)Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel;(4)Medical Division, Meuhedet Sick Fund, Tel Aviv, Israel;(5)Leumit Health Services, Leumit Health Services, Tel Aviv, Israel;(6)Rabin Medical Center and the Sackler Faculty of Medicine, Division of Gastroenterology, Petah Tikva, Israel;
DOP59: What is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participantsECCO’23 CopenhagenYear: 2023
Authors: Hart, A.(1);Miller, L.(2);Hamborg, T.(2);Stagg, I.(1);McGuinness, S.(3);Wileman, V.(4);Tzorovili, E.(2);Mihaylova, B.(2);Roukas, C.(2);Aziz, Q.(5);Czuber-Dochan, W.(3);Dibley, L.(6);Moss-Morris, R.(7);Pollok, R.(8);Saxena, S.(9);Winsor, G.(10);Norton, C.(3)*;
(1)St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom;(2)Queen Mary University of London, Pragmatic Clinical Trials Unit, London, United Kingdom;(3)King's College- London, Florence Nightingale Faculty of Nursing- Midwifery and Palliative Care, London, United Kingdom;(4)King's College London, Health Psychology-Institute of Psychiatry- Psychology and Neuroscience, London, United Kingdom;(5)Queen Mary University of London, Centre of Neuroscience- Surgery and Trauma- Blizard Institute- Wingate Institute of Neurogastroenterology, London, United Kingdom;(6)University of Greenwich, Institute for Lifecourse Development- Centre for Chronic Illness and Ageing, London, United Kingdom;(7)King's College London, Health Psychology- Institute of Psychiatry- Psychology and Neuroscience, London, United Kingdom;(8)St George's Hospital, Gastroenterology, London, United Kingdom;(9)Imperial College London, Department of Primary Care and Public Health, London, United Kingdom;(10)Crohn's & Colitis UK, Research, Hatfield, United Kingdom;
